Standard Operating Procedure for Preparation and Review of CMC Regulatory Documents

Department	Regulatory Affairs
SOP No.	RA/2026/704
Supersedes	NA
Page No.	1 of X
Issue Date	13/04/2026
Effective Date	13/04/2026
Review Date	13/04/2028

Purpose

This Standard Operating Procedure (SOP) provides a standardized and controlled approach for the preparation, review, and approval of Chemistry, Manufacturing, and Controls (CMC) regulatory documents. The objective is to ensure accuracy, completeness, compliance with relevant regulatory guidelines, and alignment with internal quality systems to facilitate timely and successful regulatory submissions and approvals.

Scope

This SOP applies to all activities related to the preparation, compilation, review, verification, approval, and management of CMC regulatory documents destined for submission to regulatory authorities. It covers all functional areas involved in the generation of CMC content including formulation, manufacturing, quality control, stability, analytical methods, validation, and regulatory affairs departments. The SOP is applicable to all dosage forms and product categories intended for human use. Activities excluded are non-CMC related regulatory documentation and post-approval maintenance protocols unless specified by regulatory requirements.

Responsibilities

The following roles are involved:

• Document Preparers: Compile and draft CMC documents based on current data and manufacturing information.
• Reviewers: Cross-check the content for technical accuracy, compliance to regulatory guidelines, and internal standards.
• Quality Assurance: Conduct final review, ensure adherence to GMP and regulatory compliance, and approve documents for submission.
• Regulatory Affairs: Coordinate the document workflow, validate completeness, and submit the finalized dossiers to regulatory agencies.
• Supervisors/Managers: Oversee the implementation of this SOP, ensure adequate training, and monitor compliance.

Accountability

The Head of Regulatory Affairs holds accountability for implementation, compliance monitoring, periodic review, escalation of issues related to CMC document controls, and ensuring the overall effectiveness of this SOP within the organization.

Procedure

The preparation and review of CMC regulatory documents shall be performed in structured phases as follows:

1. Preparation Phase: Initiate document creation after receipt of approved raw data, batch records, validation reports, and analytical results. Use standardized templates and adhere to the latest regulatory formats.
2. Prerequisites and Checks: Confirm that all input data are validated, reviewed, and approved by respective departments before inclusion. Verify that the source documentation aligns with internal quality and regulatory requirements.
3. Drafting Documents: Compile the required sections logically: product description, manufacturing processes, quality control strategies, stability data, analytical validation, and any other applicable CMC information.
4. Initial Review: The document preparer completes a self-check for consistency and completeness. Subsequently, the first-level reviewer performs a technical review focusing on scientific content and regulatory compliance.
5. GMP and Compliance Check: Quality Assurance conducts thorough review to confirm compliance with GMP standards, regulatory guidelines (e.g., ICH, FDA, EMA), and internal SOPs.
6. Deviation Handling: Any discrepancies or deviations identified during review must be documented, investigated, and resolved prior to document approval.
7. Approval: After all reviews and requisite corrections, the final document is formally approved by authorized personnel as per delegation of authority.
8. Document Control and Storage: Approved documents must be entered into the document management system with controlled versioning. Hard copies (if applicable) should be archived in designated storage areas with restricted access.
9. Submission Coordination: Regulatory Affairs compiles and formats the complete dossier for electronic or hard copy submission, ensuring adherence to agency-specific requirements.
10. Record Retention: Maintain all versions of documents, review comments, approvals, correspondence, and related records for the duration specified by regulatory and company policies.
11. Periodic Review: Documents shall be reviewed periodically or when significant changes occur in process, formulation, specifications, or regulatory guidelines to ensure ongoing accuracy.

Compliance with this procedure ensures a controlled, reproducible, and auditable approach for CMC documentation enabling regulatory approvals and continual quality assurance in pharmaceutical manufacturing environments.

Abbreviations

CMC – Chemistry, Manufacturing, and Controls
GMP – Good Manufacturing Practice
ICH – International Council for Harmonisation
FDA – Food and Drug Administration
EMA – European Medicines Agency
SOP – Standard Operating Procedure
QA – Quality Assurance
RA – Regulatory Affairs

Documents

1. CMC Document Preparation Checklist (Annexure-1)
2. CMC Regulatory Document Review Form (Annexure-2)
3. Regulatory Submission Approval Record (Annexure-3)

References

1. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
2. FDA Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls Section
3. EMA Guideline on the Chemistry, Manufacturing and Control Documentation for Marketing Authorisation
4. Company Quality Management System Documentation
5. Relevant National and International Regulatory Requirements

Version

1.0

Approval

Prepared By
Checked By
Approved By

Annexures

Annexure-1: CMC Document Preparation Checklist

Purpose: To ensure completeness and accuracy during the initial preparation of CMC regulatory documents.

Checklist Item	Status (Yes/No)	Remarks
Source data verified and available	Yes
Appropriate template used	Yes
Sections completed as per regulatory guidelines	Yes
Formatting and numbering correct	Yes
Data consistency cross-checked	Yes
Preliminary factual accuracy verified	Yes
Document labelled with draft version	Yes
Document internally circulated to reviewers	No	Pending

Annexure-2: CMC Regulatory Document Review Form

Purpose: To document technical and compliance review findings including approval or recommended actions for CMC regulatory documents.

Document Title:	CMC Drug Substance Manufacturing Process Description
Version:	Draft 1.2
Date of Review:	10/04/2026
Reviewer Name/ID:	__________________
Review Comments:	Check consistency with batch records. Clarify the process parameters for step 3. Verify references to validation reports are current.
Deviations Noted:	No
Recommended Action:	Minor clarifications needed before approval.
Review Status:	Conditional Approval
Reviewer Signature:	__________________

Annexure-3: Regulatory Submission Approval Record

Purpose: To document final approval for release and submission of the complete CMC regulatory dossier.

Submission Name:	New Drug Application Module 3 – CMC Section
Submission Date:	13/04/2026
Version Approved:	Final v1.0
Approver Role:	Head of Regulatory Affairs
Approval Date:	13/04/2026
Comments:	Reviewed all documents and confirmed regulatory readiness.
Approver Signature:	__________________

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
13/04/2026	1.0	Initial issue	New SOP creation